Open AccessClinical Efficacy and Safety of Arbekacin against Pneumonia in Febrile Neutropenia: A Retrospective Study in Patients with Hematologic Malignancies
Author(s) -
Takashi Ohashi,
Yukiyoshi Fujita,
Hiroyuki Irisawa,
Hidemasa Nakaminami,
Takahiro Arai,
Mayuko Takahashi,
Emi Momiyama,
Naoya Murata,
Kayoko Murayama,
Taeko Saito
Publication year - 2022
Publication title -
infection and chemotherapy/gam'yeom gwa hwahag yo'beob/infection and chemotherapy
Language(s) - English
Resource type - Journals
eISSN - 2092-6448
pISSN - 1598-8112
DOI - 10.3947/ic.2021.0126
Subject(s) - medicine , neutropenia , pneumonia , febrile neutropenia , pseudomonas aeruginosa , methicillin resistant staphylococcus aureus , intensive care medicine , staphylococcus aureus , chemotherapy , biology , bacteria , genetics
Arbekacin (ABK) is an aminoglycoside that exhibits anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti- Pseudomonas aeruginosa activities. Therefore, for patients with febrile neutropenia (FN) and concurrent pneumonia suspected to be caused by MRSA, ABK may be sufficiently effective even as a single agent.